ABBV vs IMA · P/E 81, rev $61.16B vs rev $9.2M
AbbVie Inc (ABBV) versus ImageneBio, Inc. (IMA) — a side-by-side from cached financials, not a winner call.
AbbVie Inc (ABBV) is a drug manufacturers - general company listed on US. It is led by Rob Michael.
ImageneBio, Inc. (IMA) is a biotechnology company listed on NASDAQ.
Latest reported ABBV revenue for 2025-12-31 was $61.16B. Net income was $4.23B. Revenue was up 305.0% from 2024-12-31 to 2025-12-31. ABBV currently screens at market cap $334.34B and trailing P/E 80.5.
Latest reported IMA revenue for 2023-12-31 was $9.2M. Net income was -$68.2M. Revenue was down 41.3% from 2022-12-31 to 2023-12-31. IMA currently screens at market cap $64.7M.
ABBV currently screens at market cap $334.34B and trailing P/E 80.5. IMA currently screens at market cap $64.7M.
Not investment advice. Open the ABBV and IMA stock pages for the full models.
Not investment advice.